The research of the domestic market of medicines and dietary supplements for obese patients pharmacotherapy

Obesity is a global social and medical problem today. In the context of the growing prevalence of obesity and the global trend towards the use of a number of medicines and dietary supplements, the relevance of their use in overweight patients is growing, including the economic aspects of this problem. The purpose of the study was to conduct a market research on medicines and dietary supplements for overweight and obese patients in the modern pharmaceutical market of Ukraine. The object of the study is information from the State Register of Medicines and information from the State Service of Ukraine on Food Safety and Consumer Protection for the last 3 years. Regulatory and legislative acts, sources of scientific literature using the Google Scholar search engine, PubMed database, Internet resources, and the Compendium reference book. The work used marketing research methods, as well as systematic review, bibliographic, graphic and documentary. According to the clinical guideline «Obesity in adults: an evidence-based guideline», the INNs liraglutide, orlistat, and the combination drug naltrexone hydrochloride/bupropion hydrochloride are approved for long-term treatment of obesity. However, Ozempic and Weight Watchers Flextouch are not included in the guidelines and standards for the treatment of obesity. The results of the study of the domestic pharmaceutical market for obesity treatment indicate that 3 foreign-made medicinal products are registered on the Ukrainian pharmaceutical market. Xenical (Orlistat, Germany) is not included in the State Register, i.e. it is not available on the pharmaceutical market, and is recommended in the guidelines. It has been established that as of the end of 2024, only Saxenda (liraglutide, Novo Nordisk, Denmark) is available in pharmacies among the drugs recommended for the treatment of obesity. Today, there is not a single domestic manufacturer in Ukraine that produces medicines for the treatment of obesity. As a result of the study, it was found that the domestic pharmaceutical market is most represented by weight loss DS in the form of capsules (57.7%), tablets (31.1%), solutions (6.7%) and powders (4.5%). DS have a combined composition of herbal medicinal raw materials, the production of which is distributed among 17 domestic and 30 foreign manufacturers. It was found that herbal teas for body weight control in Ukraine are produced mainly by domestic manufacturers: «Klyuchi Zdorovya», «Viola FF», «Phytobiotechnology», «Liktravy» and «Kamila-Pharma».